Futura Medical PLC (LON:FUM) chief executive James Barder said the company’s team is speaking to key opinion leaders in the field of erectile dysfunction ahead of publishing headline data on MED2005 later this year.
The company’s drug candidate is a fast-acting gel that eliminates some of the common side-effects of the current pill-based treatments.
Safety, dosing and efficacy are currently being assessed as part of European phase III clinical trial.
In an update alongside the company’s interim results, Barder said most of the men taking part in the double-blind study had elected to continue into the open-label safety stage during which all patients are on the highest dose of MED2005.
The gel is one of a number of products being developed by Futura, whose technology transfers drugs through the skin barrier.
It is partnered to take a pain and inflammation product to the market called TPR100 and is currently in communication with the UK regulator to clear up queries around it. It should have a response for the MHRA by the first quarter of next year, investors were told.
It has also teamed up to develop its technology to deliver CBD, the non-psychoactive element of cannabis that is linked with pain relief as well as being used to combat stress and anxiety.
The financials revealed the company had £5.63mln cash as at the end of June, while it picked up a £1.36mln research and development credit in August.
As is common for company’s at this formative stage of their development, Futura was loss-making - to the tune of £4.46mln.